Evaxion Biotech, CCIT, SSI and DTU enter into collaboration on the development of patient-tailored vaccines to attack cancer cells.
With a total grant of $ 3Million, Innovation Fund Denmark is financing a four-year research collaboration on the development of a new and promising immunotherapy; a therapeutic cancer vaccine that stimulates each patient’s own immune system to recognize and destroy cancer cells. By means of gene technology and artificial intelligence, the new immunotherapy will be customized the individual patient and eliminate the cancer cells more effectively and without the side-effects of existing therapies.
“In Evaxion, we have developed a technology platform that, by means of artificial intelligence, can identify promising antigens for vaccine candidates in infections and cancer diseases. Our role in the project is to identify the components to be used in these personalized vaccines, we believe we have found the formula for,” says Niels Møller, CMO at Evaxion. “
In the ongoing project, Evaxion is managing the process of sequencing the DNA, identifying and producing the components – the peptides – to be injected into the patient. Even though NeoPepVac has just been kick-started, the project is already progressing rapidly, and the goal is to market the new vaccine within 10 years.
Evaxion is the commercial driver of the project and will have the commercial rights for the vaccine.
“If the project succeeds, we are talking about billions of dollars. Our method can basically be applied broadly to all types of cancer – it is not limited to, for instance, breast cancer or colorectal cancer. So naturally, we are dealing with a billion-dollar potential,” says Niels Møller.